Logitech Q4 Profit Down; Cuts FY Outlook - Quick Facts

Logitech International (LOGI) reported net income of $108.21 million or $0.64 per share in the fourth quarter, down from $225.75 million or $1.31 per share in the previous year.

Non-GAAP earnings per share were $0.81 down from $1.45 last year.

Sales were $1.23 billion, down 20 percent in US dollars and 17 percent in constant currency compared to the prior year.

Logitech reduced its fiscal year 2023 outlook, removing the estimate of annual sales and profits that would have been generated in Ukraine and Russia. It reflected the current, uncertain environment in which the war in Ukraine continues without sign of resolution in the near term.

The company expects annual sales growth in constant currency to be between 2 and 4 percent, and non-GAAP operating income to be between $875 million and $925 million. Previously, sales growth in constant currency was expected to be in the mid single digits, and non-GAAP operating income was expected to be between $900 million and $950 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory. Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
Follow RTT